Overview
Compare with Harvard Bioscience, RAPID MICRO BIOSYSTEMS, INC. or EyePoint Pharmaceuticals, or pick any stock.
- TickerMASS on Nasdaq1
- IndustryLaboratory Analytical Instruments1
- HeadquartersBoston1
- Website908devices.com
- Incorporated inDE4
- Business address44 Third Avenue, Burlington, Ma 018034
- Filer categoryNon-accelerated filer, Smaller reporting company4
See how the biggest companies compare on our leaderboards
We are making chemical analysis simple, smart and speedy with our purpose-built handheld devices that empower people to take swift action in life-altering applications.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Device Sales brought in 65% of the revenue 908 Devices Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Device Sales | $31.7M | $36.7M |
| Recurring | $15.9M | $19.4M |
| Contract | $132.0K | $117.0K |
Regions
United States brought in 73% of the revenue 908 Devices Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $35.6M | $41.2M |
| EMEA | $9.1M | $10.4M |
| Asia Pacific | $2.1M | $3.0M |
| Americas other | $863.0K | $1.5M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue27¢$27.8M
- Research and development15¢$15.6M
- Selling, general and admin38¢$38.5M
- Income tax0¢$66.0K
- Profit19¢$19.5M
Out of $56.2M in revenue.7
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $56.2M | $47.7M |
| Cost of revenue | $27.8M | $23.2M |
| Gross profit | $28.4M | $24.5M |
| Research and development | $15.6M | $15.0M |
| Selling, general and administrative | $38.5M | $39.5M |
| Change in fair value of contingent consideration | $13.7M | -$13.2M |
| Goodwill impairment | $40.7M | |
| Total operating expenses | $67.8M | $81.9M |
| Loss from continuing operations | -$39.4M | -$57.4M |
| Interest income | $4.1M | $4.5M |
| Income from transition services agreement, net | $2.3M | |
| Other expense, net | -$346.0K | -$241.0K |
| Total other income, net | $6.1M | $4.3M |
| Loss from operations before income taxes | -$33.3M | -$53.1M |
| Income tax expense | $66.0K | |
| Net loss from continuing operations | -$33.3M | -$53.1M |
| Net income (loss) from discontinued operations, net of tax | $52.8M | -$19.1M |
| Net income (loss) attributable to common stockholders | $19.5M | -$72.2M |
| Net loss from continuing operations per share attributable to common stockholders, basic | -$1 | -$2 |
| Net loss from continuing operations per share attributable to common stockholders, diluted | -$1 | -$2 |
| Net income (loss) from discontinued operations per share attributable to common stockholders, basic | $1 | -$1 |
| Net income (loss) from discontinued operations per share attributable to common stockholders, diluted | $1 | -$1 |
| Net income (loss) per share attributable to common stockholders, basic | $0.54 | -$2.12 |
| Net income (loss) per share attributable to common stockholders, diluted | $0.54 | -$2.12 |
| Weighted average common shares outstanding, basic | 35.9M shares | 34.1M shares |
| Weighted average common shares outstanding, diluted | 35.9M shares | 34.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $70.5M | $44.0M | ||
| Cash and cash equivalents from continuing operations | $43.4M | |||
| Marketable securities | $42.5M | $25.6M | ||
| Accounts receivable, net of allowance for credit losses of $147 and $524 at December 31, 2025 and December 31, 2024 | $11.3M | $8.9M | ||
| Inventory | $13.0M | $10.9M | ||
| Prepaid expenses and other current assets | $7.3M | $4.2M | ||
| Current assets of discontinued operations | $10.2M | |||
| Total current assets | $144.6M | $103.1M | ||
| Operating lease, right-of-use assets | $4.4M | $3.8M | ||
| Property and equipment, net | $4.2M | $1.6M | ||
| Intangible assets, net | $36.4M | $38.7M | ||
| Other long-term assets | $471.0K | $511.0K | ||
| Non-current assets of discontinued operations | $11.8M | |||
| Total assets | $190.1M | $159.5M | ||
| Accounts payable | $1.6M | $1.4M | ||
| Accrued expenses | $6.8M | $7.2M | ||
| Deferred revenue | $8.9M | $10.4M | ||
| Operating lease liabilities | $681.0K | $1.5M | ||
| Contingent consideration | $16.0M | |||
| Current liabilities of discontinued operations | $4.7M | |||
| Total current liabilities | $34.1M | $25.1M | ||
| Operating lease liabilities, net of current portion | $3.9M | $2.6M | ||
| Deferred revenue, net of current portion | $8.3M | $10.2M | ||
| Contingent consideration, net of current portion | $2.3M | |||
| Other long-term liabilities | $30.0K | |||
| Non-current liabilities of discontinued operations | $4.6M | |||
| Total liabilities | $46.4M | $44.9M | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 36,321,866 shares and 35,098,493 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $36.0K | $35.0K | ||
| Additional paid-in capital | $366.9M | $356.2M | ||
| Accumulated other comprehensive income | $54.0K | $1.1M | ||
| Accumulated deficit | -$223.3M | -$242.8M | ||
| Total stockholders' equity | $143.7M | $114.6M | $165.5M | |
| Total liabilities and stockholders' equity | $190.1M | $159.5M | ||
| Allowance for credit losses | $147.0K | $524.0K | $389.0K | |
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 36.3M shares | 35.1M shares | ||
| Common stock, shares outstanding | 36.3M shares | 35.1M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $70.5M | $44.0M | ||
| Cash and cash equivalents from continuing operations | $43.4M | |||
| Marketable securities | $42.5M | $25.6M | ||
| Accounts receivable, net of allowance for credit losses of $147 and $524 at December 31, 2025 and December 31, 2024 | $11.3M | $8.9M | ||
| Inventory | $13.0M | $10.9M | ||
| Prepaid expenses and other current assets | $7.3M | $4.2M | ||
| Current assets of discontinued operations | $10.2M | |||
| Total current assets | $144.6M | $103.1M | ||
| Operating lease, right-of-use assets | $4.4M | $3.8M | ||
| Property and equipment, net | $4.2M | $1.6M | ||
| Intangible assets, net | $36.4M | $38.7M | ||
| Other long-term assets | $471.0K | $511.0K | ||
| Non-current assets of discontinued operations | $11.8M | |||
| Total assets | $190.1M | $159.5M | ||
| Accounts payable | $1.6M | $1.4M | ||
| Accrued expenses | $6.8M | $7.2M | ||
| Deferred revenue | $8.9M | $10.4M | ||
| Operating lease liabilities | $681.0K | $1.5M | ||
| Contingent consideration | $16.0M | |||
| Current liabilities of discontinued operations | $4.7M | |||
| Total current liabilities | $34.1M | $25.1M | ||
| Operating lease liabilities, net of current portion | $3.9M | $2.6M | ||
| Deferred revenue, net of current portion | $8.3M | $10.2M | ||
| Contingent consideration, net of current portion | $2.3M | |||
| Other long-term liabilities | $30.0K | |||
| Non-current liabilities of discontinued operations | $4.6M | |||
| Total liabilities | $46.4M | $44.9M | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 36,321,866 shares and 35,098,493 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $36.0K | $35.0K | ||
| Additional paid-in capital | $366.9M | $356.2M | ||
| Accumulated other comprehensive income | $54.0K | $1.1M | ||
| Accumulated deficit | -$223.3M | -$242.8M | ||
| Total stockholders' equity | $143.7M | $114.6M | $165.5M | |
| Total liabilities and stockholders' equity | $190.1M | $159.5M | ||
| Allowance for credit losses | $147.0K | $524.0K | $389.0K | |
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 36.3M shares | 35.1M shares | ||
| Common stock, shares outstanding | 36.3M shares | 35.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | $19.5M | -$72.2M |
| Goodwill impairment | $40.7M | |
| Depreciation and amortization expense | $4.5M | $4.7M |
| Stock-based compensation expense | $9.8M | $11.8M |
| Provision for inventory obsolescence | $513.0K | $653.0K |
| Net amortization of premiums and accretion of discounts on marketable securities | -$637.0K | $13.0K |
| Loss on disposal of property and equipment | $133.0K | $54.0K |
| Gain on sale of Desktop Portfolio, net of transaction costs | -$55.9M | |
| Provision for credit losses | $176.0K | |
| Change in fair value of contingent consideration | $13.7M | -$13.2M |
| Deferred income tax | -$283.0K | |
| Accounts receivable, net | $220.0K | -$2.9M |
| Inventory | -$3.7M | -$1.7M |
| Prepaid expenses and other current assets | -$3.0M | -$445.0K |
| Other long-term assets | $211.0K | $559.0K |
| Accounts payable and accrued expenses | -$5.9M | $2.3M |
| Deferred revenue | -$3.2M | -$368.0K |
| Right-of-use operating lease assets | $1.7M | $2.0M |
| Operating lease liabilities | -$1.7M | -$2.1M |
| Net cash used in operating activities | -$23.7M | -$30.2M |
| Purchases of property and equipment | -$955.0K | -$602.0K |
| Purchases of marketable securities | -$64.0M | -$55.5M |
| Acquisition of businesses, net of cash acquired | -$2.0M | -$44.8M |
| Proceeds from sale of Desktop Portfolio | $69.9M | |
| Proceeds from maturities of marketable securities | $47.8M | $54.6M |
| Net cash provided by (used in) investing activities | $50.7M | -$46.3M |
| Payments for withholding taxes on vested awards | -$833.0K | -$1.1M |
| Proceeds from issuance of common stock | $864.0K | $1.1M |
| Payments for contingent consideration | -$728.0K | -$417.0K |
| Net cash used in financing activities | -$697.0K | -$376.0K |
| Effect of foreign exchange rate changes on cash and cash equivalents | $27.0K | -$65.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $26.4M | -$77.0M |
| Transfers of inventory to property and equipment | $983.0K | $1.2M |
| Fair value of common stock issued for acquisition of RedWave Technology | $8.6M | |
| Cash (received) paid for income tax | -$66.0K | $184.0K |
No quarter-by-quarter statement was filed.
Corporate structure
908 Devices Inc. is part of a group headed by Repligen. 18 entities, 13 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of 908 Devices Inc.
- ARCH Venture Fund VII, L.P. Filed SCHEDULE 13G/A on 908 Devices Inc., latest Aug 14, 2026 (6 filings since Feb 8, 2022)
- ARK Investment Management LLC Filed SCHEDULE 13G/A on 908 Devices Inc., latest Aug 14, 2026 (9 filings since Feb 9, 2022)
- AWM Investment Company, Inc. Filed SCHEDULE 13G/A on 908 Devices Inc., latest Aug 14, 2026 (2 filings since Apr 7, 2025)
- BlackRock Filed SCHEDULE 13G on 908 Devices Inc., latest Jul 27, 2026 (10 filings since Jan 26, 2022)
- First Light Asset Management, LLC Filed SCHEDULE 13G/A on 908 Devices Inc., latest Feb 17, 2026 (3 filings since Nov 14, 2025)
- State Street Corporation Filed SCHEDULE 13G on 908 Devices Inc., latest Feb 9, 2026 (2 filings since Aug 11, 2025)
- Ameriprise Financial Filed SCHEDULE 13G/A on 908 Devices Inc., latest May 15, 2025 (2 filings since Feb 14, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on 908 Devices Inc., latest Jan 30, 2025 (2 filings since Feb 13, 2024)
- Granahan Investment Management, LLC Filed SC 13G/A on 908 Devices Inc., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
- EVENTIDE ASSET MANAGEMENT, LLC Filed SC 13G/A on 908 Devices Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
- ALGER ASSOCIATES INC Filed SC 13G/A on 908 Devices Inc., latest Nov 13, 2023 (3 filings since Oct 11, 2022)
- Razor's Edge Fund, LP Filed SC 13G/A on 908 Devices Inc., latest Feb 10, 2022
- Repligen Waltham, Massachusetts, United States
- 908 Devices Inc. Boston
- 908 Devices Securities Corporation Subsidiary · Massachusetts, United States
- CAM2 Technologies, LLC Subsidiary · Connecticut, United States
- Repligen Europe B.V. Subsidiary · 100% · Breda, Netherlands
- ARTeSYN Biosolutions Holdings Ireland Ltd. Subsidiary · Ireland
- ARTeSYN Biosolutions Ireland Limited Subsidiary · Ireland
- Polymem S.A. Subsidiary · France
- Repligen (Shanghai) Biotechnology Co. Ltd. Subsidiary · China
- Repligen Estonia OṺ Subsidiary · Estonia
- Repligen India Private Limited Subsidiary · India
- Repligen Ireland Limited Subsidiary · Ireland
- Repligen Japan LLC Subsidiary · Japan
- Repligen Korea Co., Ltd. Subsidiary · South Korea
- Repligen Singapore Pte. Ltd. Subsidiary · Singapore
- Repligen Sweden AB Subsidiary · Sweden
- Repligen UK Limited Subsidiary · United Kingdom
- Tantti Laboratory Inc Subsidiary · Taiwan
- 908 Devices Inc. Boston
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What 908 Devices Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $8.6M7 Dec 31, 2025 | $5.1M7 Dec 31, 2024 | +67.8% |
| Accumulated depreciation | $4.4M7 Dec 31, 2025 | $3.6M7 Dec 31, 2024 | +24.1% |
| Property and equipment, net | $4.2M7 Dec 31, 2025 | $1.6M7 Dec 31, 2024 | +165.3% |
| Operating-lease assets (leased space) | $4.4M7 Dec 31, 2025 | $3.8M7 Dec 31, 2024 | +14.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $70.5M7 Dec 31, 2025 | $44.0M7 Dec 31, 2024 | +60.1% |
| Marketable securities, current | $42.5M7 Dec 31, 2025 | $25.6M7 Dec 31, 2024 | +66.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $07 Dec 31, 2025 | $07 Dec 31, 2024 | |
| Intangible assets, net (excluding goodwill) | $36.4M7 Dec 31, 2025 | $38.7M7 Dec 31, 2024 | −5.9% |
| Finite-lived intangibles, gross | $41.2M7 Dec 31, 2025 | $40.6M7 Dec 31, 2024 | +1.5% |
| Accumulated amortization | $4.8M7 Dec 31, 2025 | $1.9M7 Dec 31, 2024 | +152.0% |
| Finite-lived intangibles, net | $36.4M7 Dec 31, 2025 | $38.7M7 Dec 31, 2024 | −5.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $13.0M7 Dec 31, 2025 | $10.9M7 Dec 31, 2024 | +19.3% |
| Raw materials | $9.6M7 Dec 31, 2025 | $7.4M7 Dec 31, 2024 | +29.8% |
| Work in process | $988.0K7 Dec 31, 2025 | $1.4M7 Dec 31, 2024 | −27.1% |
| Finished goods | $2.4M7 Dec 31, 2025 | $2.2M7 Dec 31, 2024 | +12.8% |
Properties, in its own words
Our corporate headquarters are currently located in Burlington, Massachusetts. We maintained the following principal facilities as of December 31, 2025:
Location · Functions · Square Footage (Approx.) · Lease Expiration
The rest of Item 2
Burlington, Massachusetts · Corporate headquarters, R&D · 12,800 · July 2029
Danbury, Connecticut · R&D, assembly, manufacturing · 38,200 · July 2034
Georgetown, Massachusetts · assembly, manufacturing · 3,500 · February 2030
Stamford, Connecticut · assembly, manufacturing · 11,500 · March 2028
We believe that our current facilities meet our anticipated needs for the foreseeable future.
Item 2 of the 10-K filed Mar 9, 2026.6
Leadership
Who has led 908 Devices Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerKevin J. Knopp Dec 17, 2020 to now14
- PresidentKevin J. Knopp Dec 17, 2020 to now14
- Chief financial officerJoseph H. Griffith Iv. Dec 17, 2020 to now15
Board members and other officers (17)
- SVP, Products and ProductionKevin J. McCallion Mar 4, 2026 to now16
- Chief Bus. & Strategy OfficerKolawole A. Otitoju Apr 22, 2026 to now17
- VP, Product Management & MktgMaura Fitzpatrick May 9, 2022 to Feb 3, 202318
- VP, Corporate DevelopmentNicolas Barthelemy Jun 25, 2021 to Jun 25, 202119
- Vice President, GovernmentJohn Kenneweg Dec 17, 2020 to now20
- Vice President, CommercialTrent A. Basarsky Dec 17, 2020 to Apr 28, 202221
- Board memberBrandi C. Vann Aug 18, 2025 to now22
- Board memberMichele M. Leonhart Jun 26, 2024 to now23
- Board memberAnthony Hunt Mar 4, 2022 to now24
- Board memberFenel M. Eloi Mar 2, 2021 to now25
- Board memberJeffrey P. George Mar 2, 2021 to now26
- Board memberE. Kevin Hrusovsky Dec 17, 2020 to now27
- Board memberKeith Crandell Dec 17, 2020 to now28
- Board memberKevin J. Knopp Dec 17, 2020 to now14
- Board memberMark Spoto Dec 17, 2020 to now29
- Board memberNicolas Barthelemy Dec 17, 2020 to Jun 17, 202230
- Board memberSharon Kedar Dec 17, 2020 to Dec 22, 202031
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 11, 20268-K Results of operations32
- Jul 8, 20268-K Other events33
- Jun 12, 20268-K Shareholder vote34
- May 6, 20268-K Entered a material agreement; Completed an acquisition or sale; Results of operations35
- Mar 3, 20268-K Results of operations36
- Jan 20, 20268-K Results of operations37
- Nov 10, 20258-K Results of operations38
- Aug 5, 20258-K Results of operations39
- Aug 4, 20258-K Executive or director change; Regulation FD disclosure40
- Jun 16, 20258-K Executive or director change; Regulation FD disclosure41
- Jun 13, 20258-K Shareholder vote42
- May 13, 20258-K Results of operations43
- Dec 17, 2020New chief executive Kevin J. Knopp becomes CEO14
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.15) a share, on Nov 10, 2025.44
When it reported results
- Aug 11, 2026Reported quarterly or annual results32
- May 6, 2026Reported quarterly or annual results35
- Mar 3, 2026Reported quarterly or annual results36
- Jan 20, 2026Reported quarterly or annual results37
- Nov 10, 2025Reported quarterly or annual results38
- Aug 5, 2025Reported quarterly or annual results39
- May 13, 2025Reported quarterly or annual results43
- Mar 4, 2025Reported quarterly or annual results45
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
375 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 39 major events, 216 insider forms, 44 large holders, 56 other. The latest 20:
- Oct 9, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 6, 2026144 EDGAR
- Oct 1, 20264 PRIMARY DOCUMENT EDGAR
- Sep 25, 20264 PRIMARY DOCUMENT EDGAR
- Sep 17, 20264 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 4, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 25, 2026144 EDGAR
- Aug 24, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20264 EDGAR
- Aug 12, 20264 EDGAR
- Aug 11, 2026144 EDGAR
- Aug 11, 202610-Q EDGAR
The 375 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
151 open-market trades by officers, directors and large owners since October 2021: 9 buys and 142 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | AWM Investment Company, Inc.10% owner | Sale | 24,000 | $11.36 | $272.6K | Form 4 |
| Sep 23, 2026 | AWM Investment Company, Inc.10% owner | Sale | 1,000 | $11.25 | $11.2K | Form 4 |
| Sep 17, 2026 | Kenneweg JohnSVP, Sales & Product Marketing | Sale | 5,257 | $10.22 | $53.7K | Form 4 |
| Sep 16, 2026 | Kenneweg JohnSVP, Sales & Product Marketing | Sale | 21,399 | $10.11 | $216.3K | Form 4 |
| Sep 15, 2026 | Kenneweg JohnSVP, Sales & Product Marketing | Sale | 1,000 | $10.00 | $10.0K | Form 4 |
| Sep 2, 2026 | Brown Christopher D.Director | Sale | 30,000 | $10.58 | $317.4K | Form 4 |
| Aug 25, 2026 | Griffith Joseph H. IVChief Financial Officer | Sale | 11,459 | $10.95 | $125.5K | Form 4 |
| Aug 21, 2026 | AWM Investment Company, Inc.10% owner | Sale | 41,578 | $10.61 | $441.1K | Form 4 |
| Aug 20, 2026 | AWM Investment Company, Inc.10% owner | Sale | 8,422 | $10.52 | $88.6K | Form 4 |
| Aug 17, 2026 | Knopp Kevin J.President and CEO | Sale | 20,000 | $10.35 | $207.0K | Form 4 |
| Aug 13, 2026 | Knopp Kevin J.President and CEO | Sale | 7,622 | $10.06 | $76.7K | Form 4 |
| Aug 12, 2026 | Knopp Kevin J.President and CEO | Sale | 2,747 | $10.07 | $27.7K | Form 4 |
| Aug 11, 2026 | Brown Christopher D.Director | Sale | 8,358 | $9.23 | $77.1K | Form 4 |
| Aug 11, 2026 | Knopp Kevin J.President and CEO | Sale | 145,918 | $9.90 | $1.4M | Form 4 |
| Aug 10, 2026 | Brown Christopher D.Director | Sale | 9,442 | $9.03 | $85.3K | Form 4 |
| Aug 10, 2026 | Knopp Kevin J.President and CEO | Sale | 348 | $9.06 | $3.2K | Form 4 |
| Aug 5, 2026 | Brown Christopher D.Director | Sale | 20,000 | $8.49 | $169.8K | Form 4 |
| Aug 4, 2026 | AWM Investment Company, Inc.10% owner | Sale | 50,000 | $8.36 | $418.0K | Form 4 |
| Jul 2, 2026 | Brown Christopher D.Director | Sale | 2,200 | $9.02 | $19.8K | Form 4 |
| Jul 2, 2026 | Knopp Kevin J.President and CEO | Sale | 222 | $9.07 | $2.0K | Form 4 |
All 151 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARCH Venture Fund VII, L.P.SCHEDULE 13G/A, 6 filings Feb 8, 2022 to Aug 14, 202646
- ARK Investment Management LLCSCHEDULE 13G/A, 9 filings Feb 9, 2022 to Aug 14, 202647
- AWM Investment Company, Inc.SCHEDULE 13G/A, 2 filings Apr 7, 2025 to Aug 14, 202648
- BlackRockSCHEDULE 13G, 10 filings Jan 26, 2022 to Jul 27, 202649
- First Light Asset Management, LLCSCHEDULE 13G/A, 3 filings Nov 14, 2025 to Feb 17, 202650
- State Street CorporationSCHEDULE 13G, 2 filings Aug 11, 2025 to Feb 9, 202651
- Ameriprise FinancialSCHEDULE 13G/A, 2 filings Feb 14, 2024 to May 15, 202552
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Feb 13, 2024 to Jan 30, 202553
- Granahan Investment Management, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202454
- EVENTIDE ASSET MANAGEMENT, LLCSC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202455
- ALGER ASSOCIATES INCSC 13G/A, 3 filings Oct 11, 2022 to Nov 13, 202356
- Razor's Edge Fund, LPSC 13G/A, 1 filing Feb 10, 202257
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Kevin J. Knopp, Ph.D.President and Chief Executive Officer | 53 | $500.0K | $1.6M58 |
| 2025 | Mark S. Levine Chief Legal and Administrative Officer and Secretary | 53 | $21.6K | $1.3M58 |
| 2025 | Joseph H. Griffith IVChief Financial Officer and Treasurer | 51 | $378.4K | $1.1M58 |
| 2024 | Kevin J. Knopp, Ph.D.President and Chief Executive Officer | 53 | $497.8K | $2.0M58 |
| 2024 | Joseph H. Griffith IVChief Financial Officer and Treasurer | 51 | $377.1K | $1.2M58 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How 908 Devices Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAR908 Devices Inc.2
- CIK0001555279
- Employer ID (EIN)45-45240966
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsDecember 312
- Industry code (SIC)3826 Laboratory Analytical Instruments2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address44 Third Avenue, Burlington, MA 018032
- Phone978-729-44782
- Shares outstanding41,333,705 as of Aug 7, 202613
- Public float$194.9M as of Jun 30, 20256
- AuditorPricewaterhouseCoopers, LLP, Boston, Massachusetts PCAOB ID 238; no auditor attestation of internal control over financial reporting6
- On EDGAR sinceSep 4, 20122
- Filings485 in all: 4 (245), 8-K (44), 3 (28), 144 (21), SC 13G/A (18), 10-Q (17), SCHEDULE 13G/A (13), SC 13G (12)2
All 35 form types
CORRESP (8), 10-K (6), DEF 14A (6), DEFA14A (6), S-8 (6), UPLOAD (6), D (5), SCHEDULE 13G (5), 4/A (4), ARS (4), EFFECT (4), S-1/A (4), SD (3), 424B4 (2), 8-K/A (2), DRS (2), S-1 (2), S-3 (2), SEC STAFF LETTER (2), 3/A (1), 5 (1), 8-A12B (1), CERT (1), D/A (1), DRS/A (1), DRSLTR (1), S-1MEF (1)
- Latest filingsAnnual report (10-K) Mar 9, 2026
Quarterly report (10-Q) Aug 11, 2026
Proxy statement (DEF 14A) Apr 29, 2026
Latest 8-K (8-K) Aug 11, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | MASS | Nasdaq |
From the cover page of the 10-K filed Mar 9, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks 908 Devices Inc. names in Item 1A of its 10-K filed Mar 9, 2026: 61 risks under these headings, as written.6
- Risks related to macroeconomic conditions
- Uncertainties in global economic conditions or a decline in economic conditions, such as recession, economic downturn, and/or inflationary conditions in the U.S. and other regions of the world in which we do business could impact customer spending patterns and materially and adversely affect our financial condition and operating results.
- A pandemic, epidemic or outbreak of an infectious disease may adversely affect our business.
- Risks related to our business and industry
- We have a history of net losses and may not be able to achieve profitability for any period in the future or sustain cash flow from operating activities.
- Our operating results may fluctuate significantly from period-to-period and may fall below expectations in any particular period, which could adversely affect the market price of our common stock.
- We have experienced growth of our business in recent years, and our inability to manage this growth could have a material adverse effect on our business, the quality of our products and services and our ability to retain key personnel.
- We must develop new products, as well as enhancements to existing products, and adapt to rapid and significant technological change to remain competitive.
- We need to continue to build and develop our sales, marketing and customer service organization, and to engage with domestic and international channel partners to support our planned growth.
- We face intense and growing competition from leading technology companies as well as from emerging companies. Our inability to compete effectively with any or all of these competitors could affect our ability to achieve our anticipated market penetration and achieve or sustain profitability.
- Currently, we derive substantially all of our revenue from our handheld products in the field forensics market. If we fail to maintain significant market acceptance in existing markets or fail to successfully increase our penetration in new and expanding markets, we will not generate expected revenue and our prospects may be harmed.
- Our sales cycles can be long and unpredictable, and our sales efforts require considerable time and expense, which contribute to the unpredictability and variability of our financial performance and may adversely affect our profitability.
The other 51 risks
- Due to the significant resources required to enable access in new markets, we must make strategic and operational decisions to prioritize certain markets, technology offerings or partnerships and there can be no assurance that we will expend our resources in a way that results in meaningful revenue or capitalizes on potential new markets.
- We depend on our key personnel and other highly qualified personnel, and if we are unable to recruit, train and retain our personnel, we may not achieve our goals.
- We may be unable to consistently manufacture our devices and consumables to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.
- We depend on a continued supply of components and raw materials for our products from third party suppliers, and if shortages of these components or raw materials arise, we may not be able to secure enough components to build new products to meet customer demand or we may be forced to pay higher prices for these components.
- Our current research and development efforts may not produce significant revenue for several years, if at all.
- Undetected errors or defects in our products, or errors made by the end users of our products, could harm our reputation and decrease market acceptance of our products.
- If our information technology systems or our data (or those third parties with whom we work) are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.
- Artificial intelligence presents risks and challenges that may adversely impact our business including by increasing compliance obligations and posing security risks to our confidential information, proprietary information, and personal data, and other sensitive information.
- Our international operations may raise additional risks, which could have an adverse effect on our operating results.
- Our loan and security agreement contains covenants, which restrict our operating activities, and we may be required to repay the outstanding indebtedness in an event of default, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
- Substantially all of our manufacturing operations are currently conducted at one location, and any disruption at this facility could negatively impact our operations and increase our expenses.
- Risks related to sales of products to the U.S. Government
- A significant portion of our business depends on sales to the public sector, and our failure to receive and maintain government contracts or changes in the contracting or fiscal policies of the public sector could have a material adverse effect on our business.
- U.S. government programs are limited by budgetary constraints and political considerations and are subject to uncertain future funding levels that could result in the termination of programs.
- Our contracts with the U.S. government may impose requirements that may be unfavorable to us and that may have a material adverse effect on our growth prospects and operating results.
- We are subject to audits by the U.S. government which could adversely affect our business.
- Risks related to litigation and our intellectual property
- We rely on in-bound licenses granted to us from third parties. If we lose these rights, our business may be materially adversely affected, our ability to develop improvements to our existing products and to develop new products may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation as well as the potential loss of or limitations on our ability to develop and commercialize products and technology covered by these license agreements.
- Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.
- Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- Our ability to compete and the success of our business could be jeopardized if we are unable to protect our intellectual property adequately.
- We may not be able to protect our intellectual property rights throughout the world.
- We may be obligated to disclose our proprietary technology to our customers, which may limit our ability to protect our intellectual property.
- Issued patents covering our products could be found invalid or unenforceable if challenged.
- Claims by other parties that we infringe or misuse their proprietary technology could subject us to significant liability and could force us to redesign our products or to incur significant costs.
- In the future we may be involved in litigation related to intellectual property, which could be time-intensive and costly and may adversely affect our business, financial condition, results of operations, and prospects.
- Our use of open source software could compromise our ability to offer our services and subject us to possible litigation.
- Risks related to ownership of our common stock
- If securities or industry analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.
- The market price of our common stock has been volatile and could continue to be volatile.
- Our actual operating results may differ significantly from any operating guidance we may provide.
- Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.
- We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
- We are a “smaller reporting company” and, because we have opted to use the reduced reporting requirements available to us, certain investors may find investing in our securities less attractive.
- Provisions in our certificate of incorporation, our by-laws or Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.
- Our sixth amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- Our fourth amended and restated bylaws designate specific courts in Delaware as the exclusive forum for certain litigation that may be initiated by the Company’s stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
- General Risk Factors
- If we fail to offer high quality customer service, our business and reputation could suffer.
- If we were to be sued for product liability, we could face substantial liabilities that exceed our resources.
- Repair or replacement costs due to warranties we provide on our products and consumables could have a material adverse effect on our business, financial condition, and results of operations.
- Our business has inherent operational risks that cannot be adequately covered by insurance or indemnity.
- We may be subject to governmental export controls and economic sanctions that could impair our ability to compete in international markets.
- We could be adversely affected by violations of the Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, and the anti-bribery and anti-corruption laws of the United States or other countries.
- Our employees, consultants, channel partners and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, and insider trading.
- If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company.
- We may need additional capital in the future, which may not be available to us, and if it is available, may dilute your ownership of our common stock and have a material adverse effect on our business, operating results and financial condition.
- We have in the past, and may again in the future, engage in acquisitions or divestures that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.
- We may face exposure to foreign currency exchange rate fluctuation.
- We generally recognize revenue from extended warranty and service contracts over the contract term, and changes in sales of such contracts may not be immediately reflected in our operating results.
- Our ability to use our net operating losses and certain other tax attributes may be limited.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
- We are subject to risks related to taxation in the United States.
- Future interpretations of existing accounting standards could adversely affect our operating results.
Legal proceedings
We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business.
The opening of Item 3, Legal Proceedings.6
Links
- Website908devices.com1
- X (Twitter)x.com/908devices1
- Facebookwww.facebook.com/908Devices1
- LinkedInwww.linkedin.com/company/908-devices1
- WikidataQ120997607
- SEC EDGARCIK 1555279
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1Wikidata908 Devices Inc. on Wikidata
- 2
- 3Yahoo FinanceMASS quote
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARBrandi C. Vann, Board member
- 23SEC EDGARMichele M. Leonhart, Board member
- 24SEC EDGARAnthony Hunt, Board member
- 25SEC EDGARFenel M. Eloi, Board member
- 26SEC EDGARJeffrey P. George, Board member
- 27SEC EDGARE. Kevin Hrusovsky, Board member
- 28SEC EDGARKeith Crandell, Board member
- 29SEC EDGARMark Spoto, Board member
- 30SEC EDGARNicolas Barthelemy, Board member
- 31SEC EDGARSharon Kedar, Board member
- 32SEC EDGARResults of operations
- 33SEC EDGAROther events
- 34SEC EDGARShareholder vote
- 35
- 36SEC EDGARResults of operations
- 37SEC EDGARResults of operations
- 38SEC EDGARResults of operations
- 39SEC EDGARResults of operations
- 40
- 41
- 42SEC EDGARShareholder vote
- 43SEC EDGARResults of operations
- 44NasdaqNasdaq calendar
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58